INSMED Inc Form 8-K July 19, 2017

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)** 

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 19, 2017

# **INSMED INCORPORATED**

(Exact name of registrant as specified in its charter)

Virginia (State or other jurisdiction of incorporation) 000-30739 (Commission File Number) **54-1972729** (I.R.S. Employer Identification No.)

10 Finderne Avenue, Building 10
Bridgewater, New Jersey
(Address of principal executive offices)

**08807** (Zip Code)

Registrant s telephone number, including area code: (908) 977-9900

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company O If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. O

#### Item 7.01. Regulation FD Disclosure.

As previously announced, Insmed Incorporated (the Company) will host an Analyst and Investor Day in New York City on the date hereof, and a live webcast of the event will be available through the investor relations section of the Company s website. The slide presentation to be used by the Company during the Analyst and Investor Day is attached hereto as Exhibit 99.1 and incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Insmed Incorporated Analyst and Investor Day Presentation, dated July 19, 2017.

2

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 19, 2017 INSMED INCORPORATED

By: /s/ Christine Pellizzari Name: Christine Pellizzari

Title: General Counsel and Corporate Secretary

3

### EXHIBIT INDEX

Exhibit No.	Description
99.1	Insmed Incorporated Analyst and Investor Day Presentation, dated July 19, 2017.
	4